celastrol has been researched along with deoxycytidine in 2 studies
| Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) | Studies (deoxycytidine) | Trials (deoxycytidine) | Recent Studies (post-2010) (deoxycytidine) |
|---|---|---|---|---|---|
| 885 | 1 | 741 | 18,160 | 4,652 | 8,898 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Z; Han, B; Jia, G; Jiang, H; Liu, J; Pan, S; Sun, B; Wang, Y; Zhou, H; Zhou, Y | 1 |
| Jiang, Z; Liu, Y; Tao, L; Zhao, Y | 1 |
2 other study(ies) available for celastrol and deoxycytidine
| Article | Year |
|---|---|
Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Pentacyclic Triterpenes; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Triterpenes | 2012 |
Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Repair; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Pentacyclic Triterpenes; Tumor Suppressor p53-Binding Protein 1 | 2021 |